ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Dasatinib Cube-O-Needle hybrid system for effective and safe site-specific treatment for triple-negative breast cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of the existing investigation was to design a Dasatinib (DAS) Cube-O-Needle (Cubosome-MNs hybrid system) for triple-negative breast cancer (TNBC) to improve potency and reduce side effects. In Cube-O-Needle, the Cubosome was formulated at an optimal ratio of Glyceryl monooleate (GMO), Poloxamer 407 (PLX), Soya lecithin (SL), Soluplus, and Tween 80. Hyaluronic acid (HA) was used to target DAS to TNBC cells. A risk assessment was conducted to recognize key variables. The amounts of GMO, PLX, and SL have been tailored using a Box-Behnken Design (BBD) to attain the anticipated DAS release, particle size, and zeta potential. The MTT assay was performed to evaluate the potency of DAS and its cubosomes (CUB). Cube-O-Needle was designed by infusing CUB into a microneedle patch (MNs). PMVE/MA was used to improve the mechanical characteristics and distinct needle shape. Cube-O-Needle was evaluated using various parameters. DSC, FTIR, and XRD revealed new H-bond formation and a conversion from the crystalline to the amorphous state, indicating increased solubility. The amounts of GMO, SL, and PLX were identified as significant in the FMEA analysis, and the remaining CUB were further optimized and confirmed using BBD. Optimal CUB exhibited a size of 167.2 nm, a zeta potential of - 36.5 mV, an entrapment efficiency of 79.31%, and 90% DAS release up to 12 h. The newer DAS was found to be effective against TNBC, with IC50 values of 29.68 ± 0.18 and 4.514 ± 0.10 in CUB. PMVE/MA was chosen for its mechanical strength and rapid dissolution rate. Optimized CUBs were infused into MN patches to form Cube-O-Needle, which controls DAS release for 24 h. The hybrid system Cube-O-Needle demonstrated excellent site specificity and high potency. MNs can overcome transdermal barriers, whereas CUB can release DAS for up to 24 h. DAS was effective in treating TNBC, and its CUB demonstrated greater therapeutic efficacy.
Indexed as
Identifiers
41920325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.